Super-Enhancer Reprograming Driven by SOX9 and TCF7L2 Represents Transcription-Targeted Therapeutic Vulnerability for Treating Gallbladder Cancer.
Yan S, Liu Z, Wang T, Sui Y, Wu X, Shen J, Pu P, Yang Y, Wu S, Qiu S, Wang Z, Jiang X, Feng F, Li G, Liu F, Zhao C, Liu K, Feng J, Li M, Man K, Wang C, Tang Y, Liu Y.
Yan S, et al. Among authors: li g.
Adv Sci (Weinh). 2024 Nov 4:e2406448. doi: 10.1002/advs.202406448. Online ahead of print.
Adv Sci (Weinh). 2024.
PMID: 39492805